IL6 and cancer: To determine which soluble mediators are involved in the conversion of DC2s to DC3s by SF we focused on IL-6, considering its importance in the pathology of IA, the therapeutic potential of IL-6 receptor blockers,40,41 and its known ability to facilitate the differentiation of CD14−DC2s to DC3s in cancer.18